comparemela.com

Latest Breaking News On - Blood safety - Page 8 : comparemela.com

MetLife Investment Management LLC Has $303,000 Position in Cerus Co (NASDAQ:CERS)

MetLife Investment Management LLC lessened its holdings in Cerus Co. (NASDAQ:CERS – Get Rating) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 82,977 shares of the biotechnology company’s stock after selling 9,443 shares during the quarter. MetLife Investment Management LLC’s holdings in […]

Cerus (NASDAQ:CERS) Raised to Hold at StockNews com

StockNews.com upgraded shares of Cerus (NASDAQ:CERS – Get Rating) from a sell rating to a hold rating in a report released on Tuesday. CERS has been the subject of several other research reports. BTIG Research lowered Cerus from a buy rating to a neutral rating in a research report on Friday, January 20th. Stephens downgraded […]

Cerus (NASDAQ:CERS) Rating Increased to Hold at StockNews com

Cerus (NASDAQ:CERS – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday. Several other equities analysts have also recently issued reports on CERS. BTIG Research cut shares of Cerus from a “buy” rating to a “neutral” rating in a research […]

Financial Analysis: Apyx Medical (NASDAQ:APYX) versus Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Insider & Institutional Ownership 82.5% of Cerus shares are owned […]

Critical Contrast: Cerus (NASDAQ:CERS) & Apyx Medical (NASDAQ:APYX)

Apyx Medical (NASDAQ:APYX – Get Rating) and Cerus (NASDAQ:CERS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Analyst Ratings This is a summary of current ratings and […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.